Trijardy XR
These highlights do not include all the information needed to use TRIJARDY XR safely and effectively. See full prescribing information for TRIJARDY XR. TRIJARDY XR (empagliflozin, linagliptin, and metformin hydrochloride extended-release tablets), for oral use Initial U.S. Approval: 2020
71873567-9594-452a-bb92-34a129adecac
HUMAN PRESCRIPTION DRUG LABEL
Nov 7, 2023
Boehringer Ingelheim Pharmaceuticals, Inc.
DUNS: 603175944
Products 4
Detailed information about drug products covered under this FDA approval, including NDC codes, dosage forms, ingredients, and administration routes.
empagliflozin, linagliptin, metformin hydrochloride
Product Details
FDA regulatory identification and product classification information
FDA Identifiers
Product Classification
Product Specifications
INGREDIENTS (3)
empagliflozin, linagliptin, metformin hydrochloride
Product Details
FDA regulatory identification and product classification information
FDA Identifiers
Product Classification
Product Specifications
INGREDIENTS (3)
empagliflozin, linagliptin, metformin hydrochloride
Product Details
FDA regulatory identification and product classification information
FDA Identifiers
Product Classification
Product Specifications
INGREDIENTS (3)
empagliflozin, linagliptin, metformin hydrochloride
Product Details
FDA regulatory identification and product classification information